Skip to Main Content

Advertisement

Skip Nav Destination

Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)

Cancer Res (2021) 81 (13_Supplement): CT169.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Jia Li Low
  • Sun Min Lim
  • Jii Bum Lee
  • Byoung Chul Cho
  • Ross A Soo
Therapeutic Advances in Medical Oncology (2023) 15: 175883592211461.
  • Yasir Y. Elamin
  • Jacqulyne P. Robichaux
  • Brett W. Carter
  • Mehmet Altan
  • Hai Tran
  • Don L. Gibbons
  • Simon Heeke
  • Frank V. Fossella
  • Vincent K. Lam
  • Xiuning Le
  • Marcelo V. Negrao
  • Monique B. Nilsson
  • Anisha Patel
  • R.S.K. Vijayan
  • Jason B. Cross
  • Jianjun Zhang
  • Lauren A. Byers
  • Charles Lu
  • Tina Cascone
  • Lei Feng
  • Rajyalakshmi Luthra
  • Francis A. San Lucas
  • Geeta Mantha
  • Mark Routbort
  • George Blumenschein
  • Anne S. Tsao
  • John V. Heymach
Cancer Cell (2022) 40 (7): 754.
  • Samy Chelabi
  • Xavier Mignard
  • Karen Leroy
  • Isabelle Monnet
  • Solenn Brosseau
  • Nathalie Theou-Anton
  • Marie-Ange Massiani
  • Sylvie Friard
  • Boris Duchemann
  • Elizabeth Fabre
  • Etienne Giroux-Leprieur
  • Jacques Cadranel
  • Marie Wislez
Cancers (2021) 13 (20): 5132.
  • Matthew Z Guo
  • Kristen A Marrone
  • Alexander Spira
  • Kristine Freeman
  • Susan C Scott
Oncology & Haematology (2021) 17 (1): 42.
Close Modal

or Create an Account

Close Modal
Close Modal